Form 4: Nephros Inc. Director Oliver J. Spandow Reports Stock Option Grant

Director Oliver J. Spandow reports the acquisition of 7,323 stock options in Nephros Inc.

Summary

• On May 16, 2024, Oliver J. Spandow, a director of Nephros Inc., filed a Form 4 with the SEC.
• The report details the grant of 7,323 stock options to Spandow on May 14, 2024, exercisable at a price of $2.14 per share, vesting in three tranches on 5/14/24, 5/14/25 and 5/14/26, and expiring on 05/14/2034.
• Spandow directly owns 81,604 shares of Nephros Inc. common stock.
• Spandow also holds multiple other stock option grants with varying exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants to a director, which is neither particularly positive nor negative. It's a standard corporate governance practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in similar small-cap companies.
• The size of the grant is typical for board members, but without knowing the full compensation package, it's hard to compare to industry benchmarks.
• Companies like Aethlon Medical, Inc. and Dialysis Centers of America Holdings Co. also use stock options as part of their director compensation.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates